Low N-acetylating capacity in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis
- PMID: 8589923
- DOI: 10.1111/j.1600-0625.1995.tb00211.x
Low N-acetylating capacity in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis
Abstract
Low constitutive N-acetylating capacity has been implicated as a predisposing factor for the development of adverse reactions to certain drugs. This prompted us to investigate whether the N-acetylating capacity of patients with serious cutaneous adverse reactions, i.e., Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) differed from that of healthy control subjects. N-acetylating activity was measured in hair root cells by preparing a homogenate from freshly extracted hair roots and assessing acetyl-CoA-dependent N-acetylation by RP-HPLC using 2-aminofluorene as a substrate. Samples were obtained from hospitalized patients suffering from acute SJS and TEN or from healthy controls. All patients with SJS and TEN were found to have a low N-acetylating capacity (0.85 nmol/mg/min compared to 2.21 nmol/mg/min in controls, p < 0.05). Based on these findings, a low constitutive N-acetylating capacity may be one of the predisposing factors for the development of serious cutaneous adverse reactions to drugs that require N-acetylation in these patients.
Similar articles
-
Drug-induced Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS-TEN overlap: a multicentric retrospective study.J Postgrad Med. 2011 Apr-Jun;57(2):115-9. doi: 10.4103/0022-3859.81865. J Postgrad Med. 2011. PMID: 21654132
-
Acute renal failure and its risk factors in Stevens-Johnson syndrome and toxic epidermal necrolysis.Am J Nephrol. 2009;29(6):633-8. doi: 10.1159/000195632. Epub 2009 Jan 21. Am J Nephrol. 2009. PMID: 19155617
-
Comparison of the acute ocular manifestations of Stevens-Johnson syndrome and toxic epidermal necrolysis in Chinese eyes: a 15-year retrospective study.BMC Ophthalmol. 2017 May 12;17(1):65. doi: 10.1186/s12886-017-0464-9. BMC Ophthalmol. 2017. PMID: 28499410 Free PMC article.
-
Immunological response in Stevens-Johnson syndrome and toxic epidermal necrolysis.J Dermatol. 2015 Jan;42(1):42-8. doi: 10.1111/1346-8138.12674. Epub 2014 Oct 30. J Dermatol. 2015. PMID: 25355273 Review.
-
Long-term complications of Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN): the spectrum of chronic problems in patients who survive an episode of SJS/TEN necessitates multidisciplinary follow-up.Br J Dermatol. 2017 Oct;177(4):924-935. doi: 10.1111/bjd.15360. Epub 2017 Sep 22. Br J Dermatol. 2017. PMID: 28144971 Review.
Cited by
-
Whole-Exome Sequencing in Patients Affected by Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Reveals New Variants Potentially Contributing to the Phenotype.Pharmgenomics Pers Med. 2021 Mar 1;14:287-299. doi: 10.2147/PGPM.S289869. eCollection 2021. Pharmgenomics Pers Med. 2021. PMID: 33688237 Free PMC article.
-
Toxic epidermal necrolysis.F1000Res. 2016 May 20;5:F1000 Faculty Rev-951. doi: 10.12688/f1000research.7574.1. eCollection 2016. F1000Res. 2016. PMID: 27239294 Free PMC article. Review.
-
Systemic interventions for treatment of Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome.Cochrane Database Syst Rev. 2022 Mar 11;3(3):CD013130. doi: 10.1002/14651858.CD013130.pub2. Cochrane Database Syst Rev. 2022. PMID: 35274741 Free PMC article.
-
[Emergencies in allergology].Hautarzt. 2004 Jun;55(6):525-32. doi: 10.1007/s00105-004-0735-2. Hautarzt. 2004. PMID: 15133616 Review. German.
-
New insights in toxic epidermal necrolysis (Lyell's syndrome): clinical considerations, pathobiology and targeted treatments revisited.Drug Saf. 2010 Mar 1;33(3):189-212. doi: 10.2165/11532540-000000000-00000. Drug Saf. 2010. PMID: 20158284
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources